Business Context and Reporting Period
Company: Rexahn Pharmaceuticals, Inc. (Note: Input metadata listed "Opus Genetics," but the filing text identifies the registrant as Rexahn Pharmaceuticals, Inc.)
Reporting Period: Quarter and nine months ended September 30, 2009.
Status: Development stage biopharmaceutical company focused on cancer, CNS disorders, and sexual dysfunction. The company has no commercial product sales and relies on equity financing and collaboration agreements to fund operations.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2009 | 9 Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Revenues | $56,250 | $56,250 | - |
| Net Loss | $(4,505,045) | $(3,264,124) | - |
| Accumulated Deficit | - | - | $(34,411,524) |
| Cash and Cash Equivalents | - | - | $4,141,358 |
| Restricted Cash Equivalents | - | - | $2,100,533 |
| Total Assets | - | - | $6,914,685 |
| Total Liabilities | - | - | $1,589,210 |
| Operating Cash Flow | $(3,758,540) | $(3,120,970) | - |
| Financing Cash Flow | $6,085,851 | $931,201 | - |
Note: Revenue consists entirely of amortized deferred revenue from a 2003 collaboration agreement with Rexgene Biotech Co., Ltd.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $369,130 at December 31, 2008, to $4,141,358 at September 30, 2009. This was driven by net proceeds of approximately $6.1 million from equity issuances.
- Investment Portfolio: The company sold all marketable securities (State Authority Auction Rate Bonds) held at the end of 2008, realizing a gain of $11,025. Proceeds were largely converted to cash or restricted cash.
- Expense Trends:
- General & Administrative (G&A): Increased 20.7% year-over-year (9-month) to $2.29 million, primarily due to higher stock option compensation and investor relations costs.
- Research & Development (R&D): Increased 42.3% year-over-year (9-month) to $2.02 million due to expanded clinical studies, though R&D expenses decreased 25.2% in the most recent quarter compared to the prior year quarter.
- Patent Fees: Increased 57.8% year-over-year (9-month) to $258,421 due to additional filings.
- Restricted Cash: $2.1 million is now classified as restricted cash equivalents, held in accordance with a Research and Exclusive License Option (RELO) agreement with Teva Pharmaceutical Industries Limited.
Guidance, Outlook, and Risks
- Capital Needs: Management estimates existing cash will cover operations through September 30, 2010. However, the company anticipates needing up to $9 million to fully fund its operating plan, including Phase II trials and pre-clinical studies. If additional financing is not secured, the company may need to reduce R&D activities.
- Subsequent Financing: On October 26, 2009 (post-period), the company raised $5.0 million in gross proceeds from the sale of common stock and warrants.
- Development Pipeline:
- Archexin: Phase II trials for renal cell carcinoma and pancreatic cancer; estimated cost $5.0 million to complete.
- Serdaxin: Phase II trials for depression; estimated cost $2.0 million.
- Zoraxel: Phase II trials for sexual dysfunction; estimated cost $1.5 million.
- Pre-clinical: RX-0183, RX-3117, and RX-5902 require approximately $4.5 million total for toxicology and Phase I trials.
- Legal Proceedings: Amarex, LLC filed a lawsuit alleging breach of contract seeking $93,156 plus interest. The company filed a counterclaim for $354,824 plus interest. Mediation failed, and litigation is proceeding.
- Regulatory Compliance: The company regained compliance with NYSE Amex listing standards in July 2009. FINRA closed a review of trading activity surrounding a May 2009 announcement without further action.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.1 million cash balance against the projected $9 million funding gap for the full operating plan.
- Restricted Funds: Confirm the terms of the $2.1 million restricted cash held for the Teva RX-3117 program and the conditions for its release.
- Legal Exposure: Monitor the status of the Amarex, LLC litigation and counterclaim, as a negative outcome could impact cash reserves.
- Dilution Risk: Review the impact of recent and subsequent equity offerings (including the Oct 2009 $5M raise) on existing shareholder ownership.
- Revenue Recognition: Note that current revenue is non-recurring (amortization of a 2003 payment) and does not reflect product sales; commercial sales are not expected until at least 2012.